NCT07024641 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Hepatitis B Virus Infection

Interventions

DRUG

GIGA-2339

Administered by intravenous infusion

DRUG

Placebo

Administered by intravenous infusion

Trial Locations (11)

2139

RECRUITING

Grifols Investigate Site, Concord

23284

RECRUITING

Grifols Investigative site, Richmond

30071

RECRUITING

Grifols Investigative Site, Peachtree Corners

52242

RECRUITING

Grifols Investigative Site, Iowa City

66219

RECRUITING

Grifols Investigative Site, Lenexa

77598

RECRUITING

Grifols Investigative site, Webster

78215

RECRUITING

Grifols Investigative site, San Antonio

85225

RECRUITING

Grifols Investigative site, Chandler

90805

RECRUITING

Grifols Investigative site, Long Beach

92630

RECRUITING

Grifols Investigative site, Lake Forest

92647

RECRUITING

Grifols Investigative site, Huntington Beach